European Archives - Page 1338 of 1505 - European Medical Journal

Pancreatic Cancer: The Role of Cancer-Associated Fibroblasts in Drug Metabolism

Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant disease with a 5-year survival rate of only 8%. Within the USA, PDAC is expected to become…

Endoscopic Mucosal Resection for Large Sessile Colonic Polyps (≥2 cm) Over a 9-Year Period: A Single-Centre Experience and Analysis of Changes Over Time in a University Teaching Hospital

Endoscopic mucosal resection (EMR) has become the standard technique for resection of large sessile and flat colonic polyps. We aimed to assess the…

Infliximab and Tumour Necrosis Factor Alpha Measurement on Intestinal Mucosa: A New Tool for the Clinic?

Background: Infliximab (IFX) trough levels measurement could partially explain mechanisms of loss in response to this drug.

Unsupervised Transcriptomics-Based Clustering of Ulcerative Colitis Patients Reveals Marked Heterogeneity that Relates to Anti-Tumour Necrosis Factor Treatment Response

Heterogeneity within inflammatory bowel disease cohorts is often cited as the biggest challenge to reliably studying the clinical efficacy of therapeutics.

Barrett’s Oesophagus in 2016

Barrett’s oesophagus (BO) is one of the most important complications of gastro-oesophageal reflux disease as it may progress to oesophageal adenocarcinoma.

Monoclonal Antibody-Based Therapy for Eosinophilic Oesophagitis

Eosinophilic oesophagitis is an inflammatory condition associated with marked eosinophil accumulation in the mucosal tissues of the oesophagus.

Addition of a Solid Test Meal to Oesophageal High Resolution Manometry Improves Diagnostic Yield And Identifies Dysmotility as the Cause of Patient Symptoms

The use of oesophageal high resolution manometry (HRM) to evaluate patients who present with oesophageal symptoms in the absence of a structural lesion…

Orchard Therapeutics Announces Strategic Alliance with Oxford BioMedica

United Kingdom, November 29, 2016 – Orchard Therapeutics (“Orchard”), a biotechnology company dedicated to bringing transformative ex-vivo gene therapies…

Janssen Submits Application to EMA Seeking Approval of Anti-Interleukin-23 Monoclonal Antibody Guselkumab for the Treatment of Moderate to Severe Plaque Psoriasis

Janssen announced today the submission of a Marketing Authorisation Application to the EMA seeking approval of guselkumab for the treatment of adults living with moderate to severe plaque psoriasis.

Astronauts’ Visual Impairment Involves Changes in Cerebrospinal Fluid

OCULAR impairments experienced by astronauts are linked to space-induced volume changes in cerebrospinal fluid (CSF), according to research presented…